This inventor holds 2 USPTO granted patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Akihiro Yokota: Innovator in Antisense Oligonucleotide Research
Introduction
Akihiro Yokota is a prominent inventor based in Fujisawa, Japan. He has made significant contributions to the field of molecular biology, particularly in the development of antisense oligonucleotides. With a total of 2 patents, his work focuses on innovative methods for splicing modulation of UNC13A.
Latest Patents
Yokota's latest patents include compositions and methods for splicing modulation of UNC13A. These patents describe antisense oligonucleotides that inhibit the inclusion of a cryptic exon into the mature mRNA of UNC13A. Additionally, the patents disclose pharmaceutical compositions that utilize these oligonucleotides for treating UNC13A-associated diseases or conditions related to TDP-43 dysfunction.
Career Highlights
Akihiro Yokota is currently associated with Takeda Pharmaceutical Company Limited, where he continues to advance his research. His work has garnered attention for its potential therapeutic applications in treating complex neurological disorders.
Collaborations
Yokota collaborates with notable colleagues, including Masahiro Nogami and Rumiko Ochiai. Their combined expertise enhances the research efforts in the field of antisense technology.
Conclusion
Akihiro Yokota's innovative work in antisense oligonucleotide research positions him as a key figure in the scientific community. His contributions have the potential to impact the treatment of various diseases significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile